Arrowhead Research | ARWR - Frais De Vente Et D'Administration





Frais De Vente Et D'Administration Changement Date
Agios Pharmaceuticals USD 38.46M 4.51M 2026-03
Alnylam Pharmaceuticals USD 282.51M 2.55M 2026-03
Anika Therapeutics USD 10.01M 14K 2025-12
Arrowhead Research USD 41.74M 4.28M 2026-03
Heron Therapeutics USD 23.74M 605K 2025-12
Incyte USD 328.1M 62.31M 2026-03
Ionis Pharmaceuticals USD 151M 21M 2026-03
Ligand Pharmaceuticals USD 20.84M 4.19M 2026-03
Merck USD 2.67B 180M 2026-03
Moderna USD 173M 135M 2026-03
Nektar Therapeutics USD 10.17M 10.17M 2025-12
Novartis USD 3.14B 296M 2026-03
Sarepta Therapeutics USD 54.03M 51.35M 2026-03
TG Therapeutics USD 73.14M 22.42M 2026-03
Ultragenyx Pharmaceutical USD 88M 1000K 2026-03
Vertex Pharmaceuticals USD 493.7M 6.7M 2026-03
Xencor USD 82.12M 65.08M 2026-03